Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three ...

The study participants reflected a diverse population of MASH patients. About 56% had type 2 diabetes, and approximately 73% were classified as obese. This suggests that semaglutide may be ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

All participants also received standard care for MASH. Participants got two liver biopsies to help evaluate the effects of semaglutide. About 56% of participants had type 2 diabetes, and about 73% ...

In a new study, semaglutide reduced liver fat, inflammation, and scarring in people with MASH. Patients also saw improvements in weight, blood sugar, and insulin resistance. Experts say ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...